Literature DB >> 6126794

Conformational restrictions of biologically active peptides via amino acid side chain groups.

V J Hruby.   

Abstract

Determining the relationships between conformation and biological activity in peptide hormones and neurotransmitters is an important goal of contemporary biology. A major difficulty in these studies is the conformational flexibility of most peptides and the high dependence of the conformations on environment. The question arises whether conformations determined in solution are relevant to those important to the peptide at the membrane receptor(s). One recent approach to overcome these difficulties has been the use of conformational constraints by covalent bonding of side chain groups of residues in the peptide. In this manner linear peptides are rendered cyclic, and cyclic peptides are further conformationally constrained either by ring contractions or by other conformational constraints. Biologically active peptides specifically designed by this approach have been found to possess several useful properties including: 1) greater conformational integrity; 2) increased agonist or antagonist potency; 3) prolonged biological activity; 4) increased enzymatic stability; and 5) increased specificity for a particular receptor. Careful applications of this approach have provided important new designs features for peptide structure-function studies, and new insights into peptide conformation-activity relationships for oxytocin, somatostatin, enkephalin, bradykinin, vasopressin, and other biologically active peptides.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6126794     DOI: 10.1016/0024-3205(82)90578-1

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  47 in total

1.  Design of novel peptide ligands which have opioid agonist activity and CCK antagonist activity for the treatment of pain.

Authors:  V J Hruby; R S Agnes; P Davis; S-W Ma; Y S Lee; T W Vanderah; J Lai; F Porreca
Journal:  Life Sci       Date:  2003-06-27       Impact factor: 5.037

2.  Approaches to the rational design of selective melanocortin receptor antagonists.

Authors:  Victor J Hruby; Minying Cai; Joel Nyberg; Dhanasekaran Muthu
Journal:  Expert Opin Drug Discov       Date:  2011-03-24       Impact factor: 6.098

3.  Topological side-chain classification of beta-turns: ideal motifs for peptidomimetic development.

Authors:  Tran Trung Tran; Jim McKie; Wim D F Meutermans; Gregory T Bourne; Peter R Andrews; Mark L Smythe
Journal:  J Comput Aided Mol Des       Date:  2005-11-23       Impact factor: 3.686

Review 4.  Development of delta opioid peptides as nonaddicting analgesics.

Authors:  R S Rapaka; F Porreca
Journal:  Pharm Res       Date:  1991-01       Impact factor: 4.200

Review 5.  The Melanocortin Receptor System: A Target for Multiple Degenerative Diseases.

Authors:  Minying Cai; Victor J Hruby
Journal:  Curr Protein Pept Sci       Date:  2016       Impact factor: 3.272

Review 6.  Peptidomimetics, a synthetic tool of drug discovery.

Authors:  Josef Vagner; Hongchang Qu; Victor J Hruby
Journal:  Curr Opin Chem Biol       Date:  2008-05-14       Impact factor: 8.822

Review 7.  Organic chemistry and biology: chemical biology through the eyes of collaboration.

Authors:  Victor J Hruby
Journal:  J Org Chem       Date:  2009-12-18       Impact factor: 4.354

8.  Role of membrane lipids in peptide hormone function: binding of enkephalins to micelles.

Authors:  C M Deber; B A Behnam
Journal:  Proc Natl Acad Sci U S A       Date:  1984-01       Impact factor: 11.205

9.  Effects of conformational constraint in 2- and 8-cycloleucine analogues of oxytocin and [1-penicillamine] oxytocin examined by circular dichroism and bioassay.

Authors:  I Fric; J Hlavacek; T W Rockway; W Y Chan; V J Hruby
Journal:  J Protein Chem       Date:  1990-02

10.  Beta-turn secondary structure and melanocortin ligands.

Authors:  Erica M Haslach; Jay W Schaub; Carrie Haskell-Luevano
Journal:  Bioorg Med Chem       Date:  2008-03-04       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.